Name : Hussein Osman Ammar
Date and Place of Birth: 15.6.1943, Menia, Egypt.
Occupation
:
 Chairman,
Department
of
Pharmaceutical
Technology, Faculty of Pharmaceutical Sciences
and Pharmaceutical Industries, Future University
in Egypt.
 Professor of Pharmaceutical Technology, Department of Pharmaceutical
Technology, National Research Centre, Dokki, Cairo, Egypt.
1948 – 1952
Student, primary school
1952 – 1956
Student, preparatory school
1956 – 1959
Student, secondary school
1959 – 1964
Undergraduate student, Faculty of Pharmacy, Cairo University
1964 – 1965
Pharmacist, Improvement and Development Department,
Chemical Industries Development Inc.
1965 – 1970
Research
Associate,
Department
of
Pharmaceutical
Sciences, National Research Centre, Cairo as well as
postgraduate
student,
Faculty
of
Pharmacy,
Cairo
University.
1968
Obtained M. Pharm. Degree in Pharmacy (Pharmaceutics),
grade excellent, Cairo University, on the basis of a thesis
entitled “A Study of Certain Technological Aspects
Concerning the Stability of Injectable L- Ascorbic Acid
Solutions”
1970
Obtained
Ph.D.
Degree
in
Pharmaceutical
Sciences
(Pharmaceutics), Cairo University, on the basis of a thesis
entitled “A contribution to the Solubility and Stability of
Riboflavine”
1971 – 1976
Research Staff Member, Department of Pharmaceutical
Sciences, National Research Centre
1976 – 1981
Associate Research Professor, Department of Pharmaceutical
Sciences, National Research Centre, Cairo
1976 – 1980
Teaching,
undergraduate
students,
Pharmaceutical
Technology and Physical Pharmacy, Faculty of Pharmacy,
Assiut University
1976 – 1980
Teaching, Postgraduate Students, Physical Pharmacy,
Faculty of Pharmacy, Assiut University
1976
Postdoctoral Grant, British Royal Society, School of
Pharmacy, Manchester University, U.K.
1981 till now
Professor of Pharmaceutical Technology, National Research
Centre
1987 – 2005
Co-chairman,
Scientific
Permanent
Committee
of
Pharmaceutical Sciences, National Research Centre
1991 – 1995
Vice-Dean, Pharmaceutical Industries Research Division
National Research Centre
1994 till now Active Member, New YorkAcademy of Sciences
1995 – 1997
Chairman, Department of Pharmaceutical Sciences, National
Research Centre
1995
Scientific Mission, Academy of Sciences, Czech Republic.
1996
Biographee, Who’s Who in the World, 14 th edition.
1997 – 2000
Chairman, Pharmaceutical Industries Research Division,
National Research Centre
2001 – 2008
Teaching,
undergraduate
students,
Pharmaceutical
Technology and Physical Pharmacy, Faculty of Pharmacy,
Suez – Canal University
2001 – 2008
Teaching,
postgraduate
students,
Physical
Pharmacy,
Faculty of Pharmacy, Suez – Canal University
2007
Teaching
undergraduate
students,
Pharmaceutics
and
Physical Pharmacy, Faculty of Pharmacy, 6th October
University
2007 – 2009
Chairman, Department of Pharmaceutical Technology,
National Research Centre
2008 till now
Teaching,
undergraduate
students,
Pharmaceutical
Technology and Clinical Pharmacy, Faculty of Pharmacy,
Future University
2012 till now
Chairman, Department of Pharmaceutical Technology,
Faculty of Pharmaceutical Sciences and Pharmaceutical
Industries, Future University
Teaching Experience:
1976 – 1980
Teaching,
undergraduate
students,
Pharmaceutical
Technology and Physical Pharmacy, Faculty of Pharmacy,
Assiut University
1976 – 1980
Teaching, Postgraduate Students, Physical Pharmacy,
Faculty of Pharmacy, Assiut University
2001 till now
Teaching,
undergraduate
students,
Pharmaceutical
Technology and Physical Pharmacy, Faculty of Pharmacy,
Suez – Canal University
2001 till now
Teaching,
postgraduate
students,
Physical
Pharmacy,
Faculty of Pharmacy, Suez – Canal University
2007
Teaching
undergraduate
students,
Pharmaceutics
and
Physical Pharmacy, Faculty of Pharmacy, 6th October
University
2008 till now
Teaching
undergraduate
students,
Pharmaceutical
Technology and Clinical Pharmacy, Faculty of Pharmacy,
Future University
Participation in Research Projects:
1. Principal Investigator, Research Project financed by Academy of
Scientific Research and Technology, entitled “Studies on the
Bioavailability of Drugs under Local Conditions” (1984 – 1987).
2. Co-principal Investigator, Research Project financed by Academy
of Scientific Research and Technology, entitled “Rubber Articles
for Medical and Pharmaceutical Uses” (1984 – 1987).
3. Consultant, Project no. 4 – 13 – 43, Bilharsiasis National Research
Project, Ministry of Public Health - AID (1991 – 1994).
4. Principal Investigator, Research Project financed by Academy of
Scientific Research and Technology, entitled "A study on the
Bioavailability of Selected Drugs and Reasons for their
Unstability" (1995 – 1998).
5. Principal Investigator, Mega Project financed by National Research
Centre, entitled "Application of Nanotechnology for Delivering
and Improving the Therapeutic Efficacy of Selected Drugs” (2008
– 2010).
6. Principal Investigator, Research Project financed by Ministry of
Trade and Industry and Ministry of Higher Education and State for
Scientific Research, entitled "Development of a drug delivery
system for administration of insulin by oral route" (2008 – 2010).
Participation in International Conferences:
1. Third
European
Congress
of
Biopharmaceutics
and
Pharmacokinetics, Freiburg, Germany (1987).
2. 47th Congress of Pharmaceutical Sciences of FIP, Amsterdam, The
Netherlands (1987).
3. 5th International Conference on Pharmaceutical Technology, Paris,
France (1989).
4. Fourth
European
Congress
of
Biopharmaceutics
and
Pharmacokinetics, Geneva, Switzerland (1990).
5. 54th Congress of Pharmaceutical Sciences of FIP, Lisbon, Portugal
(1994).
6. 57th Congress of Pharmaceutical Sciences of FIP, Vancouver,
Canada (1997).
7. 7th Commonwealth Pharmaceutical Association Conference and
Pharmacy Australian Congress, Melbourne, Australia (1999).
8. 60th Congress of Pharmaceutical Sciences of FIP, Vienna, Austria
(2000).
9. 61st Congress of Pharmaceutical Sciences of FIP, Singapore (2001).
10.British Pharmaceutical Conference, Manchester, U.K. (2004).
11.65th Congress of Pharmaceutical Sciences of FIP, Cairo, Egypt
(2005).
12.XIII International Cyclodextrin Symposium, Torino, Italy (2006).
13.British Pharmaceutical Conference, Manchester, U.K. (2006).
14.1st International Conference on Drug Design & Discovery Dubai,
UAE (2008).
15.15thInternational Cyclodextrin Symposium, Vienna, Austria (2010).
Publications: Two patents, 6 patents (under review) and 110 scientific
research papers.
Prizes:
1. Awarded the First Class Medal for Science and Arts by President
of the Arab Republic of Egypt (2013).
2. Awarded the Golden Medal of the Academy of Scientific
Research and Technology (2013).
3. Awarded the Appreciation State Prize in the realm of Advanced
Technological Sciences ‫״‬Medical Sciences‫( ״‬2010).
4. Awarded the National Research Centre Prize for Scientific
Appreciation (2009).
5. Awarded the Scopus Award for Scientific Contribution to
Pharmacology (2008).
6. Awarded the National Research Centre Prize for Scientific
Distinction (1994).
Thesis Supervision: 19 M. Pharm. Theses and 10 Ph.D. Theses.
International Activities:
1. Active Member, New York Academy of Sciences.
2. Reviewer, Discovery and Innovation.
3. Reviewer, Drug Development and Industrial Pharmacy.
4. Reviewer, Journal of Inclusion Phenomena and Macrocyclic Chemistry.
5. Reviewer, Current Drug Delivery.
6. Reviewer, Expert opinion on Drug Metabolism and Toxicology.
7. Reviewer, Recent Patents on Drug Delivery and Formulation.
8. Reviewer, International Journal of Pharmaceutical Sciences.
9. Reviewer, Asian Journal of Pharmaceutical Sciences.
10.Reviewer, Journal of Carbohydrate Polymers.
11.Reviewer, Journal of Current Nanoscience.
Prof. Dr. Hussein Osman Ammar
List of Publications
I. Scientific papers
(1969)
1. On heavy metal ions contamination from ampoule glass.
Kassem, M.A., Kassem, A.A. and Ammar, H.O., Pharm. ActaHelv.
44, 535.
2. Studies on the stability of injectable L-ascorbic acid solutions.
I. Effect of pH, solvent, light and container.
Kassem, M.A., Kassem, A.A. and Ammar, H.O., ibid. 44, 611.
3. Studies on the stability of injectable L-ascorbic acid solutions.
II. Effect of metal ions and oxygen content of solvent water.
Kassem, M.A., Kassem, A.A. and Ammar, H.O., ibid. 44, 667.
(1972)
4. Studies on the stability of injectable L-ascorbic acid solutions.
III. Effect of metal complexing agents.
Kassem, M.A., Kassem, A.A. and Ammar, H.O., ibid. 47, 89.
(1975)
5. Studies on the stability of injectable solutions of some phenothiazines.
I. Effect of pH and buffer systems.
Ammar, H.O., Salama, H.A. and El-Nimr, A.E.M., Pharmazie 30,
368.
6. Studies on the stability of injectable solutions of some phenothiazines.
II. Effect of chelating agents and antioxidants.
Ammar, H.O., El-Nimr, A.E.M. and Salama, H.A., ibid. 30, 369.
(1976)
7. Stability of injection solutions of vitamin B1.
I. Influence of chelating agents.
Ammar, H.O., ibid. 31, 235.
8. Stability of injection solutions of vitamin B1.
II. Influence of lipoic acid.
Ammar, H.O., ibid. 31, 373.
9. On the solubilization properties of surfactant-polymer complexes.
Ammar, H.O., ibid. 31, 784.
10. On the rheology of polyoxyethylene sorbitol lanolin derivatives.
Salama, H.A., Ammar, H.O. and El-Nimr, A.E.M.,
FetteSeifenAnstrichmittel78, 317.
11. On the influence of liquid derivatives of lanolin on the rheology of
hydrocarbon ointmentbases.
Salama, H.A., El-Nimr, A.E.M. and Ammar, H.O., ibid. 78, 319.
(1977)
12. On the dissolution and bioavailability of phenindione.
I. Phenendione tablets.
Ammar, H.O., Kassem, M.A., Salama, H.A. and El-Ridy, M.S., Pharm.
Ind. 39, 171.
13. On the dissolution and bioavailability of phenindione.
II. Dissolution rate of phenindione powder and solid dispersions.
Salama, H.A., Kassem, M.A., Ammar, H.O. and El-Ridy, M.S., ibid.
39, 290.
14. On the dissolution and bioavailability of phenindione.
III. Dissolution and bioavailability of phenindione capsules.
Kassem, M.A., Salama, H.A., Ammar, H.O. and El-Ridy, M.S., ibid.
39, 396.
15. Interaction between thiamine hydrochloride and lipoic acid.
Ammar, H.O. and Salama, H.A., Pharmazie32, 34.
16. Effect of beeswax on the rheological characteristics of soft paraffin.
Salama, H.A and Ammar, H.O., FetteSeifenAnstrichmittel79, 154.
17. A paper chromatographic method for separation and determination of
synephrinein injectable solutions.
El-Nimr, A.E.M., Ammar, H.O. and Salama, H.A., Pharmazie32, 402.
(1979)
18. Rheological studies on Macaloid dispersions.
I. Effect of preservatives.
Salama, H.A. and Ammar, H.O., Pharm. Ind.41, 89.
19. Effect of some hydrotropic agents on the water solubility of
aminophenazone.
Ibrahim, S.A., Ammar, H.O., Kassem, A.A. and Abu- Zaid, S.S.,
Pharmazie34,809.
(1980)
20. On the dissolution of digoxin.
Kassem, M.A., Ammar, H.O., Salama, H.A. and El-Ridy, M.S., Pharm.
Ind.42, 757.
21. Solubilizing benzothiadiazide diuretics by Cetomacrogol 1000.
Ammar, H.O. and Salama, H.A., ibid. 42, 849.
22. Solubility of chlorothiazide and hydrochlorothiazide in mixed aqueous
solvent system
Ibrahim, S. A., Ammar, H.O. and El-Faham, T.H., Proc. 2nd Intern.
Pharm. Conf. Pharm. Technol., Paris, France, June 3-5.
23. Interaction of aromatic monocarboxylic acid derivatives with
amidopyrine.
Ammar, H.O., Ibrahim, S.A., Kassem, A.A. and Abu- Zaid, S. S.,
Pharm. Ind. 42, 1312.
24. Studies on some factors affecting stability of isoniazid solutions.
I. Effect of pH - value and buffer system.
Ibrahim, S.A., Ammar, H.O. and Abd El- Mohsen, M.G., Bull. Pharm.
Sci., AssiutUniversity3, 25.
(1981)
25. Effect of alcohols on the rheological characteristics of Macloid
dispersions.
Salama, H.A. and Ammar, H.O., Pharmazie36, 15.
26. Effect of polyvinylpyrrolidone on the rheological characteristics of
Macloid dispersions.
Salama, H.A. and Ammar, H.O., ibid. 36, 262.
27. Interaction between bendroflumethiazide and caffeine.
Ammar, H.O. and Salama, H.A., ibid. 43, 265.
28. Effect of sodium salts of toluic acids on the water solubility of
riboflavine.
Ammar, H.O. and Salama, H.A., Pharm. Ind.43, 194.
29. Interaction of chlorothiazide and hydrochlorothiazide with certain
amides, imides andxanthines.
Ammar, H.O., Ibrahim, S.A. and El- Faham, T.H., ibid. 43, 292.
30. On the dissolution of chlorothiazide powders and solid dispersions.
Salama, H.A., Ammar, H.O., Kassem, M.A. and El-Ridy, M. S., ibid. 43,
1242.
(1982)
31. Effect of aromatic hydrotropes on the solubility of some
benzothiadiazines.
Ammar, H.O., Ibrahim, S.A. and El- Faham, T.H., Pharmazie37, 36.
32. Effect of chelating agents on the stability of inectable isoniazid
solutions.
Ibrahim, S.A., Ammar, H.O. and Abd El- Mohsen, M.G., ibid. 37, 272.
33. On the dissolution of chlorothiazide and hydrochlorothiazide tablets and
capsules.
Ammar, H.O., Kassem, M.A., Salama, H.A. and El-Ridy, M.S., Bull.
Nat. Res. Centre, Egypt7, 75.
34. On the dissolution of hydrochlorothiazide powders and solid
dispersions.
Kassem, M.A., Salama, H.A., Ammar, H.O. and El-Ridy, M.S., Pharm.
Ind.44, 1186.
35. Complex formation between antihistaminic drugs and caffeine.
Mattha, A. G., Ammar, H.O., Abdel-Samie, M., El-Nahhas, S.A. and
Kassem, M.A.,
Pharm. Acta.Helv.57, 268.
(1983)
36. Interaction of pheothiazines and caffeine.
I. Complex formation.
Ammar, H.O., Mattha, A.G., Abdel-Samie, M., El-Nahhas, S.A. and
Kassem, M.A.,ibid. 58, 23.
37. Interaction of pheothiazines and caffeine.
II. Effect of complexation with caffeine on the stability and in-vitro
transport of phenohiazines.
Abdel- Samie, M., Ammar, H.O., Mattha, A.G., El-Nahhas, S.A. and
Kassem, M.A., ibid. 58, 28.
(1989)
38. Solubilizing of glucocorticoids with cetomacrogol.
Ammar, H.O. and Omar , S.M., Pharm.Ind.51, 1450.
(1991)
39. Interaction of pheothiazines with xanthines.
I. Interaction of pheothiazineswith caffeine.
Ammar, H.O., Elmahrouk, G., Omar, S.M., El-Nahhas, S.A. and
Kassem, M.A., ibid. 53, 786.
40. Interaction of pheothiazines with xanthines.
II. Interaction of phenothiazineswith theophylline.
Elmahrouk, G., Ammar, H.O., Omar, S. M., El-Nahhas, S.A. and
Kassem, M.A., ibid.53, 868.
41. Interaction of pheothiazines with xanthines.
III. Effect of complexation with xanthines on the bioavailability of
chlorpromazine.
Ammar, H.O., Omar, S. M., El-Nahhas, S.A. and Kassem, M.A., ibid.
53, 959.
(1992)
42. Interaction of glucocorticoids with xanthines.
Ammar, H.O., El-Nahhas, S. A., Omar, S. M. and Khalil, R. M.,
Egypt.J. Pharm. Sci.33, 981.
(1993)
43. Discrepancy among dissolution rates of commercial tablets as a
function of dissolution method.
I. Prednisolone tablets.
Ammar, H.O., Khalil, R. M. and Omar, S. M., Pharmazie48, 57.
44. Discrepancy among dissolution rates of commercial tablets as a
function of dissolution method.
II. Paracetamol tablets.
Ammar, H.O. and Khalil, R.M., ibid. 48, 129.
45. Discrepancy among dissolution rates of commercial tablets as a
function of dissolution method.
III. In vitro/in vivo correlation for paracetamol tablets.
Ammar, H.O. and Khalil, R.M., ibid. 48, 136.
46. Effect of aromatic hydrotropes on the solubility of allopurinol.
I. Effect of sodium salts of hydroxy and amino derivatives of benzoic
acid.
Ammar, H.O. and El-Nahhas, S.A., ibid. 48, 436.
47. Effect of aromatic hydrotropes on the solubility of allopurinol.
II. Effect of nicotinamide and sodium salts of benzoic, naphthoic and
nicotinic acids.
Ammar, H.O. and El-Nahhas, S.A., ibid. 48, 534.
48. Effect of aromatic hydrotropes on the solubility of allopurinol.
III. Effect of sodium salts of toluic acids.
Ammar, H.O. and El-Nahhas, S.A., ibid. 48, 751.
49. Effect of aromatic hydrotropes on the solubility of phenacetin.
I. Effect of sodium salts of hydroxy and amino derivatives of benzoic
acid.
Ammar, H.O. and Khalil, R.M., ibid. 48, 842.
50. Effect of aromatic hydrotropes on the solubility of phenacetin.
II. Effect of nicotinamide and sodium salts of benzoic, naphthoic and
nicotinic acids.
Ammar, H.O., Omar, S.M. and Khalil, R. M., ibid. 48, 845.
51. Discrepancy among dissolution rates of commercial tablets as a
function of dissolution method.
IV. Chloropromazine hydrochloride tablets.
Ammar, H.O., Omar, S.M. and Khalil, R. M., ibid. 48, 927.
52. Discrepancy among dissolution rates of commercial tablets as a
function of dissolution method.
V. In vitro/in vivo correlation for chlorpromazine hydrochloride
tablets.
Ammar, H.O., Khalil, R.M. and Omar, S.M., ibid. 48, 932.
(1994)
53. Evaluation of antischistosomal effect of praziquantel in a liposomal
delivery system.
Ammar, H.O., El- Ridy, M.S., Ghorab, M. and Ghorab, M.M., Int. J.
Pharm. 103, 237.
54. Interaction of allopurinol with phenylephrine and certain analgesics.
Ammar, H.O., El-Nahhas, S.A., Omar, S. M. and Khalil, R.M., J.
Drug Res., Egypt 21, 65.
55. Solubilization ofbromhexine hydrochloride by non -ionic surfactants.
Ammar, H.O. and El-Nahhas, S.A., Pharmazie49, 583.
56. Effect of aromatic hydrotropes on the solubility of carbamazepine.
I. Effect of sodium salts of hydroxy and amino derivatives of benzoic
acid.
Ammar, H.O. and Omar, S.M., Egypt. J. Pharm. Sci. 35 ,189.
57. Effect of aromatic hydrotropes on the solubility of carbamazepine.
II. Effect of nicotinamide and sodium salts of benzoic, naphthoic and
nicotinic acids.
Ammar, H.O. and Omar, S.M., ibid. 35, 209.
58. Solubilization of carbamazepine hydrochloride by non -ionic
surfactants.
Ammar, H.O. and Omar, S.M. ,Pharmazie49, 746.
59. Solubiliztion of allopurinol with methyl xanthines.
Ammar, H.O., El-Nahhas, S.A., Khalil, R.M. and Omar, S.M. ibid.
49,839.
(1995)
60. Improvement of some pharmaceutical properties of drugs by
cyclodextrin complexation.
I. Allopurinol.
Ammar, H.O. and El-Nahhas, S.A., ibid.50, 49.
61. Improvement of some pharmaceutical properties of drugs by
cyclodextrin complexation.
II. Colchicine.
Ammar, H.O. and El-Nahhas, S.A., ibid.50, 269.
62. Improvement of some pharmaceutical properties of drugs by
cyclodextrin complexation.
III. Bromhexine hydrochloride.
Ammar, H.O. and El-Nahhas, S.A., ibid. 50, 408.
63. Improvement of some pharmaceutical properties of drugs by
cyclodextrin complexation.
IV. Chlorpromazine hydrochloride.
Ammar, H.O., Ghorab, M., El-Nahhas, S.A., Omar, S.M. and Ghorab,
M.M., ibid. 50, 805.
(1996)
64. Effect of aromatic hydrotropes on the solubility of oxamniquine.
I. Effect of sodium salts of hydroxy and amino derivatives of benzoic
acid.
Ammar, H.O. and Khalil, R.M., ibid. 50, 809.
65. Improvement of some pharmaceutical properties of drugs by
cyclodextrin complexation.
V. Theophylline.
Ammar, H.O., Ghorab, M., El-Nahhas, S.A., Omar, S.M. and Ghorab,
M. M., ibid. 51, 42.
66. Improvement of some pharmaceutical properties of drugs by
cyclodextrin complexation.
VI. Ampicillin.
Ammar, H.O., El-Nahhas, S.A. and Ghorab, M.M., ibid. 51, 568.
67. Discrepancy among dissolution rates of commercial tablets as a
function of dissolution method.
VI. Rifampicin.
Ammar, H.O. and Khalil, R.M., ibid. 51, 165.
68. Effect of aromatic hydrotropes on the solubility of oxamniquine.
II. Effect of nicotinamide and sodium salts of benzoic, naphthoic,
nicotinic and isonictinic acids.
Ammar, H.O. and Khalil, R.M., ibid. 51, 490.
69. Solubilization of certain analgesics by Cetomacrogol 1000.
Ammar, H.O. and Khalil, R.M., Egypt. J. Pharm. Sci. 37, 261.
70. Interaction of dicumarol with β- cyclodextrin.
Ammar, H.O., Ghorab, M., El-Nahhas, S.A., Omar, S.M. and Ghorab,
M.M., ibid.37, 431.
71. Interaction of hydrochlorothiazide with β- cyclodextrin.
Ammar, H.O., Ghorab, M., El-Nahhas, S.A., Omar, S.M. and Ghorab,
M.M., ibid. 37, 445.
(1997)
72. Discrepancy among dissolution rates of commercial tablets as a
function of dissolution method.
VII. Aspirin.
Ammar, H.O., El-Nahhas, S.A., Emara, L.H., Ghorab, M.M. and Salama,
H.A., Pharmazie52, 145.
73. Improvement of some pharmaceutical properties of drugs by
cyclodextrin complexation.
VII. Trimethoprim.
Ammar, H.O., El-Nahhas, S.A. and Emara, L.H., ibid. 52, 376.
74. Improvement of the biological performance of oral anticoagulant
drugs.
I. Warfarin.
Ammar, H.O., Ghorab, M., El-Nahhas, S.A. and Makram, T.S., ibid.
52, 627.
75. Improvement of the biological performance of oral anticoagulant
drugs.
II. Dicumarol
Ammar, H.O., Ghorab. M., El-Nahhas, S.A. and Makram, T.S., ibid.
52, 727.
76. Preparation and evaluation of sustained – release solid dispersions of
drugs with Eudragit polymers.
Ammar, H.O. and Khalil, R.M., Drug Devel. Ind. Pharm. 23, 1043.
77. Interaction of oral anticoagulants with methyl xanthines.
Ammar, H.O., Ghorab, M., El-Nahhas, S.A. and Makram, T.S.,
Pharmazie52, 946.
78. Dissolution rate as a predictory tool for assessing comparative
bioavailability of generic ampicillin capsules.
Ammar, H.O., El-Nahhas, S.A. and Khalil, R.M., Egypt.J. Pharm. Sci.
38, 527.
(1998)
79. Cyclodextrin in acetazolamide eye drops formulations.
Ammar, H.O., El- Nahhas, S.A. and Khalil, R.M., Pharmazie53, 559.
80. Liposomal delivery systems in hydrocortisone eye drops formulation.
Salama, H.A., Ammar, H.O. and Khalil, R. M., Egypt.J. Pharm. Sci.
39, 19.
81. Liposomal delivery systems in timolol maleate eye drops formulation.
Salama, H. A., Ammar, H.O. and Khalil, R. M., ibid. 39, 109.
(1999)
82. Inclusion complexation of furosemide in cyclodextrins.
I. Effect of cyclodextrins on the physicochemical characteristics of
furosemide.
Ammar, H.O., Ghorab, M., Emara, L.H., El- Nahhas, S.A. and Makram,
T.S., Pharmazie54, 142.
83. Inclusion complexation of furosemide in cyclodextrins.
II. Implication on bioavailability.
Ammar, H.O., Ghorab, M., Emara, L.H., El- Nahhas, S.A. and Makram,
T.S., ibid.,54, 207.
(2000)
84. Design of slow – release furosemide.
Ammar, H.O., Ghorab, M., El- Nahhas, S.A. and Makram, T.S.,
Pharmacy World Congress 2000, Vienna, Austria 26 – 31 August.
(2001)
85. Design of dexamethazone eye drops with prolonged effect.
Ammar, H.O., Salama, H.A., Ghorab, M., El- Nahhas, S.A. and
Elmotasem, H., Pharmacy World Congress 2001, Singapore 1 – 6
September.
(2004)
86. A transdermal delivery system for glipizide.
Ammar, H.O., Salama, H.A., Ghorab, M., El- Nahhas, S.A. and
Elmotasem, H., J. Pharm. Pharmacol.56, S - 41.
(2005)
87. Design and evaluation of prednisolone acetate eye drops with
prolonged effect.
Ammar, H.O., Salama, H.A., Ghorab, M., El - Nahhas, S.A. and
Elmotasem, H., Egypt.J. Pharm. Sci. 46, 9.
88. A transdermal delivery system for aspirin as an antithrombotic drug.
Ammar, H.O., Ghorab, M., El - Nahhas, S.A. and Kamel, R., British
Pharmaceutical Conference, Manchester, U.K.
(2006)
89.Formulation and biological evaluation ofglimepiride–cyclodextrin–
polymer systems.
Ammar, H.O.,Salama, H.A.,Ghorab, M. and Mahmoud,A.A., Int. J.
Pharm.309,129.
90. Implication of inclusion complexation of glimepiride incyclodextrin–
polymer systems on its dissolution,stability and therapeutic efficacy.
Ammar, H.O.,Salama, H.A.,Ghorab, M. and Mahmoud,A.A.,
ibid.,320, 53.
91. A Transdermal Delivery System for Glipizide.
Ammar,
H.O.,
Salama,
H.A.,
Ghorab,
M.,
El
–Nahhas,
S.A.andElmotasem, H., Current Drug Delivery, 3, 333.
92. Design of a transdermal delivery system for aspirin as an
antithrombotic drug.
Ammar, H.O., Ghorab, M., El - Nahhas, S.A.andKamel, R., Int. J.
Pharm.,327, 81.
(2007)
93. Inclusion Complexation of Glimepiride in Dimethyl-β-Cyclodextrin.
Ammar, H.O., Salama, H.A., Ghorab, M. and Mahmoud, A.A., Asian
Journal of Pharmaceutical Sciences, 2, 44.
94. Physicochemical and biological evaluation of chemical penetration
enhancers for transdermal delivery of aspirin.
Ammar, H.O., Ghorab, M., El - Nahhas, S.A.andKamel, R., ibid.,2,
96.
95. Nanoemulsions for delivering warfarin transdermally.
Ammar, H.O., Salama, H.A., Ghorab, M., El - Nahhas, S.A. and El
Feky,
G.S.,
1st
Conferance
on
Material
Sciences
and
Nanonotechnology “Future Challenges”,National Research Centre,
Cairo, Egypt.
96. Extended release of tramadol hydrochloride using polymeric matrix
system via transdermal route.
Ammar, H.O., Ghorab, M., El - Nahhas, S.A. and Kamel, R., 1st
Conferance on Material Sciences and Nanonotechnology “Future
Challenges”,National Research Centre, Cairo, Egypt.
(2008)
97. Design and evaluation of chitosan films for transdermal delivery of
glimepiride.
Ammar, H.O.,Salama, H.A., El-Nahhas, S.A., and Elmotasem, H.,
Current Drug Delivery,5, 290.
98. Polymeric matrix system for transdermal delivery of tramadol
hydrochloride.
Ammar, H.O., Ghorab, M., El - Nahhas, S.A. andKamel, R., 1st
International Conference on Drug Design & Discovery, February 4-7,
Dubai, UAE.
(2009)
99.
Polymeric matrix system for prolonged delivery of tramadol
hydrochloride, Part I: Physicochemical evaluation.
Ammar, H.O., Ghorab, M., El - Nahhas, S.A. andKamel, R., AAPS
PharmSciTech, 10, 7.
100. Polymeric matrix system for prolonged delivery of tramadol
hydrochloride, Part II: Biological evaluation.
Ammar, H.O., Ghorab, M., El - Nahhas, S.A. andKamel, R.,
ibid.10, 1065.
101. Nanoemulsion as a potential ophthalmic delivery system for
dorzolamide hydrochloride.
Ammar, H.O., Salama, H.A., Ghorab, M. andMahmoud, A.A., AAPS
PharmSciTech, 10, 808.
(2010)
102. Development of dorzolamide hydrochloride in situ gel nanoemulsion
for ocular delivery.
Ammar, H.O., Salama, H.A., Ghorab, M. and Mahmoud, A.A., Drug
Dev. Ind. Pharm., 36, 1330.
(2011)
103.Proniosomes as a carrier system for transdermal delivery of tenoxicam.
Ammar, H.O., Ghorab, M., EL - Nahhas, S.A.and Higazy, I.M., Int. J.
Pharm., 405, 142.
104.Preparation and evaluation of hydrogels as a vehicle for topical delivery
of lornoxicam.
Ammar, H.O., Ghorab, M. and Mahmoud, A.A., Makram, T.S. and
Noshi, S.H., Int. J. Drug Formulation & Research, 2.
(2012)
105. Chitosan /cyclodextrinnaoparticles as drug delivery system.
Ammar, H.O., El-Nahhas, S.A., Ghorab, M.M. andSalama,A.H., J. Incl.
Phenom. Macrocycl. Chem., 136, 127.
106. Novel microemulsions as transdermal delivery systems for enhanced
efficacy of fluoxetine hydrochloride.
Ammar, H.O., Badawi, A.A, Mostafa, D.M and Abou-Taleb, S.A.,
Asian J. of Pharmaceutical Sciences and Research 2 , issue 4.
107. Topical liquid crystalline gel containing lornoxicam/cyclodextrin
complex.
Ammar, H.O., Ghorab, M. and Mahmoud, A.A., Makram, T.S. and
Noshi, S.H., J. Incl. Phenom. Macrocycl. Chem., 73, 161.
108. Rice bran oil: preparation and evaluation of novel liquisolid and
semisolid formulations.
Ammar, H.O., Al-Okbi, S.Y., Mostafa, D.M. and Helal, A.M., Int. J.
Pharm. Compounding, 16, 516.
(2013)
109. Host-guest system of etodolac in native and modified β-cyclodextrins:
preparation and physicochemical characterization.
Ammar, H.O., Ghorab, M., Mostafa, D.M., Makram, T.S. and Ali,
R.M., J. Incl Phenom Macrocycl Chem., 77, 121-134.
110. Rapid pain relief using transdermal film forming polymeric solution of
ketorolac.
Ammar, H.O., Ghorab, M. and Mahmoud, A.A., Makram, T.S. and
Ghoneim, A.M., Pharm. Dev. Technol., 18, 1005-16.
II. Patents
1.
A new method for preparing stable injectable L- ascorbic acid
solutions.
Kassem, M.A. and Ammar, H.O., Egypt. Pat. 10032 (1969).
2.
A method for preparing sustained release insulin beads.
Ammar, H.O., El- Ridy, M. S., Abdallah, N.A., Soror, M.H., Gamal,
A.M., Ezz, H.A. and Shaalan, H.F., Egypt. Pat. 23187 (2004).
3.
Investigation of the transdermal bioavailability of aspirin.
Ammar, H.O., Ghorab M., El – Nahhas, S.A. and Kamel, R., ibid.
Appl. 2005030122, March 14th, 2005.
4.
Innovation of new pharmaceutical formulation of warfarin for
transdermal use.
Ammar, H.O., Salama, H.A., Ghorab, M., El – Nahhas, S.A. and El –
Feky, G.S., ibid. Appl. 2005030145, March 22nd, 2005.
5.
Innovation of new pharmaceutical formulation for glimepiride tablets
characterized by high therapeutic efficacy.
Ammar, H.O., Salama, H.A., Ghorab, M. and Mahmoud, A.A., ibid.
Appl. 2005050248, May 22nd, 2005.
6.
Innovation of a transdermal delivery system for tramadol.
Ammar, H.O., Ghorab M., El – Nahhas, S.A. and Kamel, R., Egypt.
Pat. Appl. 2006070361, January 3rd, 2006.
7.
Innovation of a new gelatine product from wastes of birds for food and
pharmaceutical industries.
Ammar, H.O., Mostafa, E.M., Egypt. Pat. Appl. 2007.
8.
Innovation of a new formulation for dorzolamide hydrochloride eye
drops characterized by high therapeutic efficacy.
Ammar, H.O., Salama, H.A., Ghorab and Mahmoud, A.A., Egypt.
Pat., Appl. 20080400666, April 4th, 2008.